Humana Tax Repeal, And Other News: The Good, Bad, And Ugly Of Healthcare

|
About: Humana Inc. (HUM), Includes: CLRB, TRXC
by: Avisol Capital Partners
This article is exclusive for subscribers.
Avisol Capital Partners
Long/short equity, newsletter provider, healthcare, biotech
Summary

Humana will benefit from Trump's tax repeal.

Cellectar receives an orphan drug designation.

TransEnterix tanks on some corporate updates.

Humana (HUM) had a pretty decent 2019 as its stock rallied over 30 percent, delivering solid returns to investors. I don't generally cover non-pharma stocks, but this rally, coupled with some interesting news